U3-1402 Racks Up 42.9% Response Rate in Breast Cancer Study: Daiichi Sankyo

Daiichi Sankyo’s potential first-in-class HER3-targeting antibody drug conjugate (ADC), U3-1402, delivered an overall response rate of 42.9% in a PI/II study enrolling patients with heavily pretreated HER3-positive metastatic breast cancer, according to the latest data. The updated study results, which...read more